Piper Jaffray Companies restated their overweight rating on shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) in a research note issued to investors on Thursday, The Fly reports. They currently have a $5.00 price target on the biotechnology company’s stock.
Other research analysts also recently issued reports about the stock. Needham & Company LLC raised shares of Genocea Biosciences from a hold rating to a buy rating and set a $12.00 target price on the stock in a research note on Monday, July 24th. Cowen and Company reissued a buy rating and set a $10.00 price objective on shares of Genocea Biosciences in a research report on Tuesday, September 26th. Zacks Investment Research raised shares of Genocea Biosciences from a hold rating to a buy rating and set a $1.75 price objective on the stock in a research report on Monday, October 16th. Stifel Nicolaus downgraded shares of Genocea Biosciences from a buy rating to a hold rating and reduced their price objective for the company from $15.00 to $2.50 in a research report on Monday, September 25th. Finally, ValuEngine raised shares of Genocea Biosciences from a sell rating to a hold rating in a research report on Monday, July 24th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the stock. Genocea Biosciences presently has an average rating of Buy and an average price target of $7.62.
Shares of Genocea Biosciences (GNCA) traded up $0.22 during midday trading on Thursday, hitting $1.27. 1,348,165 shares of the company traded hands, compared to its average volume of 818,334. The company has a current ratio of 2.97, a quick ratio of 2.97 and a debt-to-equity ratio of 0.56. Genocea Biosciences has a 12 month low of $1.04 and a 12 month high of $7.29.
Genocea Biosciences (NASDAQ:GNCA) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.08). During the same period in the prior year, the firm earned ($0.45) EPS. analysts anticipate that Genocea Biosciences will post -1.9 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Piper Jaffray Companies Reaffirms “Overweight” Rating for Genocea Biosciences, Inc. (GNCA)” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.com-unik.info/2017/11/06/piper-jaffray-companies-reaffirms-overweight-rating-for-genocea-biosciences-inc-gnca.html.
Institutional investors have recently modified their holdings of the business. GSA Capital Partners LLP bought a new stake in shares of Genocea Biosciences during the 2nd quarter valued at $100,000. Ameriprise Financial Inc. boosted its holdings in shares of Genocea Biosciences by 11.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 22,233 shares of the biotechnology company’s stock valued at $119,000 after buying an additional 2,300 shares in the last quarter. State of Wisconsin Investment Board bought a new stake in shares of Genocea Biosciences during the 2nd quarter valued at $125,000. Rhumbline Advisers bought a new stake in shares of Genocea Biosciences during the 2nd quarter valued at $157,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Genocea Biosciences during the 2nd quarter valued at $159,000. 57.53% of the stock is currently owned by institutional investors and hedge funds.
About Genocea Biosciences
Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.
What are top analysts saying about Genocea Biosciences Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Genocea Biosciences Inc. and related companies.